Literature DB >> 11359682

The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.

J Dinnes1, C Cave, S Huang, K Major, R Milne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11359682     DOI： 10.3310/hta5130

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  11 in total

1.  Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.

Authors:  Janne A Martikainen; Akseli Kivioja; Taru Hallinen; Pia Vihinen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.

Authors:  Jean-Blaise Wasserfallen; Sandrine Ostermann; Serge Leyvraz; Roger Stupp
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

3.  Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme.

Authors:  S E Combs; S Gutwein; Ch Thilmann; P Huber; J Debus; D Schulz-Ertner
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.

Authors:  Peter S Hall; Claire Hulme; Christopher McCabe; Yemi Oluboyede; Jeff Round; David A Cameron
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.981

5.  Economics of Malignant Gliomas: A Critical Review.

Authors:  Jeffrey J Raizer; Karen A Fitzner; Daniel I Jacobs; Charles L Bennett; Dustin B Liebling; Thanh Ha Luu; Steven M Trifilio; Sean A Grimm; Matthew J Fisher; Meraaj S Haleem; Paul S Ray; Judith M McKoy; Rebecca DeBoer; Katrina-Marie E Tulas; Mohammed Deeb; June M McKoy
Journal:  J Oncol Pract       Date:  2014-12-02       Impact factor: 3.840

6.  Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

Authors:  S Chibbaro; L Benvenuti; A Caprio; S Carnesecchi; F Pulerà; F Faggionato; D Serino; C Galli; M Andreuccetti; N Buxton; R Gagliardi
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

7.  Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

Authors:  Ayman I Omar; Warren P Mason
Journal:  Core Evid       Date:  2010-06-15

8.  The cytotoxic effect of β-elemene against malignant glioma is enhanced by base-excision repair inhibitor methoxyamine.

Authors:  Yongjian Zhu; Jue Hu; Fang Shen; Hong Shen; Weiguo Liu; Jianmin Zhang
Journal:  J Neurooncol       Date:  2013-05-23       Impact factor: 4.130

9.  Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.

Authors:  Gabriel Rogers; Ruth Garside; Stuart Mealing; Martin Pitt; Rob Anderson; Matthew Dyer; Ken Stein; Margaret Somerville
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.

Authors:  J Dinnes; C Cave; S Huang; R Milne
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.